Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Explore this paper's citation graph
Summary
Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival thanThose who received placebo, regardless of the presence or absence of homologous-recombination deficiency.
- Type
- article
- Published
- 2019-09-28
- Cited by
- 1,793
- References
- 26
- Access
- Open access
- OpenAlex
- https://openalex.org/W2975141952
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:205103748
Keywords
Ovarian cancer, Medicine, Oncology, Cancer, Gynecology
References
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
- An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer.
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
- Interim analysis: the alpha spending function approach.
- FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication
- Integrated Genomic Analyses of Ovarian Carcinoma
- Incorporation of bevacizumab in the primary treatment of ovarian cancer.
- Validation of the EORTC QLQ-C30 quality of life questionnaire through combined qualitative and quantitative assessment of patient-observer agreement.
- Mechanistic Rationale for Inhibition of Poly(ADP-Ribose) Polymerase in ETS Gene Fusion-Positive Prostate Cancer
- BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancers
- Validation of the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) Symptom Index (FOSI) in a phase II clinical trial of pertuzumab in patients with advanced ovarian cancer
- Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors.
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
- Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores.
- Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
- Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer.
- Safety and dose modification for patients receiving niraparib
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Cited by
- CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
- Tumor Treating Fields for Ovarian Carcinoma: A Modeling Study
- The effect of PARP inhibitors in homologous recombination proficient ovarian cancer: meta-analysis
- Standard changing news der Senologie und der Gynäkologischen Onkologie 2018
- Breast cancer surveillance following ovarian cancer in BRCA mutation carriers.
- Emerging serine-threonine kinase inhibitors for treating ovarian cancer
- Latest clinical evidence of maintenance therapy in ovarian cancer.
- Mechanisms of PARP inhibitor resistance in ovarian cancer.
- Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
- Aberrant sialylation in ovarian cancers
- Secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: are we missing something?
- European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.
- The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition.
- A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
- Maintenance Therapy in the Primary Treatment of Epithelial Ovarian Cancer.
- Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
- [PARP inhibitors in first-line of ovarian cancers].
- Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer
- A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, Intravenous/Intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
Related papers
- The effect of fasting on tissue cyclic cAMP and plasma glucagon in the obese hyperglycemic mouse.
- Exogenous glucocorticoids and a high-fat diet cause severe hyperglycemia and hyperinsulinemia and limit islet glucose responsiveness in young male Sprague-Dawley rats.
- Modulation of adipoinsular axis in prediabetic zucker diabetic fatty rats by diazoxide.
- Growth hormone binding protein in the rat: effects of gonadal steroids
- Growth hormone binding protein in the rat: effects of gonadal steroids.
- Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance.
- Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance.
- Anterior pituitary type II thyroxine 5'-deiodinase activity is not affected by lesions of the hypothalamic paraventricular nucleus which profoundly depress pituitary thyrotropin secretion.
- Cortistatin Is a Key Factor Regulating the Sex-Dependent Response of the GH and Stress Axes to Fasting in Mice.
- The impact of euglycemia and hyperglycemia on stimulated pituitary hormone release in insulin-dependent diabetics.